B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

32.47 +1.47 (+4.73%)
Streaming Delayed Price Updated: 10:46 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story ↗
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗
Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
My Top 10 Portfolio Holdings for 2026 ↗
This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come. 
Via The Motley Fool
Topics Stocks
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today ↗
Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? ↗
Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Glenview Capital Management Sells $71 Million of Alight Stake After Stock's 71% Drop ↗
Glenview Capital Management reduced its stake in Alight by roughly 16% during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing ↗
Glenview Capital Management added to its massive position in Teva Pharmaceuticals stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,... 
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗
Stanley Druckenmiller is considered one of the greatest investors of all time. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗
Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries. 
Via Stocktwits
Topics ETFs
News headline image
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season. 
Via Stocktwits
Topics Economy Government
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA. 
Via Investor's Business Daily
Topics Economy Government
News headline image
Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report ↗
Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform. 
Via Benzinga
Topics Law Enforcement
News headline image
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023 ↗
Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Teva Pharmaceutical Indus ↗
 
Via Benzinga
News headline image
Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗
Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps. 
Via Benzinga
News headline image
Why Teva Pharmaceutical Stock Rocked the Market Today ↗
The company delivered a convincing pair of beats in its third-quarter earnings report. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook ↗
Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now $2.55–$2.65. 
Via Benzinga
News headline image
Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides
In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week... 
Via MarketMinute
Topics Economy Intellectual Property Supply Chain
News headline image
Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike ↗
Teva stock jumped Wednesday on better-than-expected quarterly metrics. 
Via Investor's Business Daily
Topics Earnings
News headline image
Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock ↗
Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock 
Via The Motley Fool
Topics ETFs Economy Regulatory Compliance
News headline image
Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally ↗
Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares ↗
Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares 
Via The Motley Fool
News headline image
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.